Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 23,729 Shares

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. sold 23,729 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $12.08, for a total value of $286,646.32. Following the sale, the insider now directly owns 3,028,958 shares in the company, valued at $36,589,812.64. This trade represents a 0.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 14th, Saba Capital Management, L.P. sold 600 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.04, for a total value of $7,224.00.
• On Tuesday, May 13th, Saba Capital Management, L.P. sold 730 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $8,964.40.
• On Wednesday, May 7th, Saba Capital Management, L.P. sold 1,366 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.19, for a total value of $16,651.54.
• On Thursday, April 17th, Saba Capital Management, L.P. sold 9,144 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.78, for a total value of $107,716.32.
• On Monday, April 14th, Saba Capital Management, L.P. sold 15,400 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.67, for a total value of $179,718.00.
• On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.14, for a total value of $335,937.84.
• On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total value of $79,705.73.
• On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.28, for a total value of $357,372.56.
• On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total value of $611,677.34.
• On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total value of $428,315.22.

Abrdn Life Sciences Investors Price Performance

HQL stock traded up $0.13 on Monday, reaching $12.46. The company had a trading volume of 145,727 shares, compared to its average volume of 103,950. Abrdn Life Sciences Investors has a 1 year low of $10.55 and a 1 year high of $15.90. The company’s fifty day moving average is $12.28 and its 200 day moving average is $13.31.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

Institutional investors and hedge funds have recently bought and sold shares of the stock. Absolute Investment Advisers LLC purchased a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $5,242,000. Raymond James Financial Inc. purchased a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $3,129,000. LPL Financial LLC lifted its stake in Abrdn Life Sciences Investors by 82.0% in the 4th quarter. LPL Financial LLC now owns 287,095 shares of the company’s stock valued at $3,767,000 after buying an additional 129,313 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $1,594,000. Finally, Commonwealth Equity Services LLC lifted its stake in Abrdn Life Sciences Investors by 3.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company’s stock valued at $395,000 after buying an additional 933 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.